atabecestat: Clinical Trials

3 trials of atabecestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Completed 1
Phase 31Terminated 1

Follow atabecestat: new trials by email Literature Review of atabecestat trials Research Report on atabecestat

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo - Asymptomatic Amyloid-positive
Phase 2 / Phase 3TerminatedJanssen Research & Development, LLC5572015-10-292025-04-29
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, Placebo - Alzheimer Disease
Phase 2TerminatedJanssen Research & Development, LLC902015-07-022025-04-29
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
JNJ-54861911, 10 milligram (mg), JNJ-54861911, 50 mg, Placebo - Alzheimer's Disease
Phase 2CompletedJanssen Research & Development, LLC1142014-11-012025-04-29

Conditions studied

Alzheimer Disease (3)  ·  Dementia (1)

Sponsors

Janssen Research & Development, LLC (3)

Countries

Belgium (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Sweden (3)  ·  France (2)  ·  Australia (1)  ·  Canada (1)  ·  Denmark (1)  ·  Finland (1)  ·  Japan (1)  ·  Mexico (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 32410694, PMID 33464300, PMID 39559869

NIH funding

2014 (2), 2015 (1)